| Term 
 
        | Non SteroidalAnti-Inflammatory drugs (NSAIDs)/ Non-Opoid Analgesics  MOA |  | Definition 
 
        | All NSAIDs, incl acetimanophen, inhibit prostaglandin synthesis via inhibition of the prostaglandin synthetase family of enzymes, specifically inhibiting cycloxygenase (COX), to one degree or another. 
All NSAIDs, except acetaminophen are anit-inflammatory |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | as analgesic- HA, muscle ache, joint pain, anti-pyretic, anti-inflammatory treat inflamm. cond. e.g arthritis, ASA inhibits platelet aggregation |  | 
        |  | 
        
        | Term 
 
        | Acetaminophen (APAP) (N-acetl-parap-aminophenol) *paracetamol * (phenacetin metabolized to APAP) |  | Definition 
 
        | non- opiate analgesic with NO anti-inflammatory effects. |  | 
        |  | 
        
        | Term 
 
        | Method of Action of salicylates |  | Definition 
 
        | Inhibits prostaglandin synthesis by inhibiting cyclooxygenase.  Prostaglandins normally cause hyperalgesia: make pain receptors more sensitive to other pain mediators (i.e. serotonin, substance P, bradykining) Increase response to painful stimili, so reduce PGs will decrease response. Inhibiting prostaglandin synthesis with both peripheral and central actions. |  | 
        |  | 
        
        | Term 
 
        | what role do prostaglandines play in antipyretic effect of NSAIDs? |  | Definition 
 
        | 
PGs in hypothalamus increase body temperature via an increase in cAMP. 
ASA has a central effect to inhibit prostaglandins in hypothalamus thus decr. high body temperature by increased vasodilation and sweating. 
ASA has no effect on normal temperature. |  | 
        |  | 
        
        | Term 
 
        | 
what role does prostaglindin play in the anti-inflammatory effect of ASA? |  | Definition 
 
        | Relates to peripheral inhibition of cyclo-oxygenase enzyme. Cell damage tiggers inflammation which releases PGs and others PGs may sensitize receptors to other inflammatory mediators: 5-HT, bradykining, histamine. 
Inhibit PG synthesis effective to relieve inflamation.note that phagocytes migrate into area and cause lysozomal enzymes to be released with subsequent lysozomal enzymes and tissue damage that increases  inflammation. But prostaglanding inhibitors do not block this. |  | 
        |  | 
        
        | Term 
 
        | what role does prostaglindin play in the platelet aggregation effect of ASA? |  | Definition 
 
        | ASA is most effective because irreversible acetylation of the cyclooxygenase enzyme, thus  inhibits synthesis. PGs (thromboxane A2) are involved in stimulating platelet aggregation. proven useful in decreasing risk in thrombolytic diseases |  | 
        |  | 
        
        | Term 
 
        | what role does prostaglindin play in the gastrointestinal effect of ASA & NSAIDs? |  | Definition 
 
        | 
salicylates and all NSAIDs cause GIT disturbances because harm stomach's ability to protect itself. 
Ulceration, bleeding, anemia & perforation may result. 
A prostaglandin may be protective in stomach- stimulates mucous and bicarb secretion, inhibit H+ secretion and cause vasodilation. |  | 
        |  | 
        
        | Term 
 
        | effect of ASA and NSAIDs on respiration |  | Definition 
 
        | high doses increase respiration, deep rapid rate blows off all our CO2 leads to respiratory alkalosis (elevated blood pH). |  | 
        |  | 
        
        | Term 
 
        | what are the uses of aspirin? |  | Definition 
 
        | mild to moderate pain relief. |  | 
        |  | 
        
        | Term 
 
        | is aspirin selective or non-selective? |  | Definition 
 
        | non-selctive inhibitor of cyclooxygenase (inhibit COX1 and COX 2 very well) |  | 
        |  | 
        
        | Term 
 
        | what are the metabolic effects of NSAIDs? |  | Definition 
 
        | aspirin/ acetysalicylic acid if really high dose will uncouple oxidative phosphorylation[the link b/w respiratory activity and storage of energy as ATP --> leads to fever, inreased O2 consumption, increased heat production] in overdose and especially in children |  | 
        |  | 
        
        | Term 
 
        | pharmokinietics of aspirin |  | Definition 
 
        | ASA hydrolyzes to salicylic acid (still active, 1/2 life 6-30hrs) but once deacytelated can no longer irreversibly bind to cyclooxygenase.  ASA ( 1/2 life 30mins). so increased dose of ASA, means more salicylic acid (metabolized in liver mainly), means slower elimination -> increased concen. and increased toxicities |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | GIT: upset, nausea, vomiting, ulceration,  bleeding (anemia) 
Serious overdose (esp children: note methyl salicylate/winter green oil used in baking and candy making can be toxic to kids.)Hypersensitivity: anaphlylaxis (cross reactive to other NSAIDs), 25% are sensitive to aspirin with no immunologic reaction. Small percetn of pts are actually allergic to aspiring: sensitized lymphocytes.Intoxication: Low dose = tinnitus, dizziness, HA, confusionIntoxication: higger doses "salicylism"= nausea, vomitting, diarrhea, hypernea, acid/base problems, hemorrhage Tx: supportive.Reye's syndrome: oif kids <15 get aspirin after flu/chicken pox/ viral dsease causes nerve damage and liver problems. yes give kids acetaminophen.(aspirin increases uric acid levels in  body, inhibits the transport mechanisms (similar to thiazides and loop diruetics) |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | analgesic, anti-pyretic anti-inflammatory |  | 
        |  | 
        
        | Term 
 
        | overdose in aspirin can cause |  | Definition 
 
        | fever, diarrhea, hypernea, acid/base problems, hemorrhage, can kill you (lethal dose = 20g) |  | 
        |  | 
        
        | Term 
 
        | Method of action of Acetaminophen (APAP) |  | Definition 
 
        | inhibits COX enzyme but does NOT work well in periphery. [ other non-opiate analgesics inhibit COX 1 and COX2 enzyme ]   |  | 
        |  | 
        
        | Term 
 
        | Acetaminophen (APAP) USES |  | Definition 
 
        | good analgesia fever reduction, NO anti-inflammatory No platelet inhibtion NO increase in uric acid No risk of Reye's syndrome (can use in chilren) Problem in pts with GOUT less water retention. 
   
 |  | 
        |  | 
        
        | Term 
 
        | Acetaminophen (APAP)  OVERDOSE Toxicities |  | Definition 
 
        | OVERDODE mainly: APAP metabolized to toxic oxygen intermediate by p450 in the liver and the kidney; if not neuralized by gluthatione then: hepatic necrosis Renal necrosis Hypoglycemia Coma Death Fatal dose = 25g (all the gluthatione used up) |  | 
        |  | 
        
        | Term 
 
        | Acetaminophen Toxicities: Early Symptoms of  Overdose w/in 24 hrs |  | Definition 
 
        | Muld nausea, vomiting, anorexia, pain Can treat early overdose with N-ACETYL CYSTEINE (antidote in first 10 hours to increase conjuction of toxic metabolite. 
Alcohol depletes glutatione; potentiates effects. |  | 
        |  | 
        
        | Term 
 
        | Acetaminophen Toxicities: 2 to 6 days after Overdose w/in 24 hrs |  | Definition 
 
        | acetaminophen metabolized to highly reactive intermediates then: hepatic damage, liver failure, bleeding, jaundice, death |  | 
        |  | 
        
        | Term 
 
        | NON-opiate analgesic NSAIDs uses |  | Definition 
 
        | analgesic, antipyretics, anti-inflammatory. treate Rheumatoid arthritis, chronic inflammatory diseases.. All INHIBIT PROSTAGLANDIN SYNTHESIS (INHIBIT COX enzyme) |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | leukotriene, hetes and other inflammatory mediators made INSTEAD of prostaglandins. pt can be cross senstive to NSAIDs (inhibit COX enzymes) and aspirin.   |  | 
        |  | 
        
        | Term 
 
        | Can pt taking acetaminopen(APAP) be cross-sensitive to aspirin? |  | Definition 
 
        | no because APAP does not cause peripheral effects |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | 10=25% of pts that have one of the following will have aspirin sensitivity: 1. Asthma 2. Nasal Polyps, 3. Chronic uticaria. 
only 1% of poupulation have aspirin sensitivity or "aspirin tolerance" |  | 
        |  | 
        
        | Term 
 
        | Chronic use of NSAIDS can cause |  | Definition 
 
        | 
Fluid accummulation due to effects on kidney fct.increased risk of gastric problems |  | 
        |  | 
        
        | Term 
 
        | NSAIDs has what ocular toxicities? |  | Definition 
 
        | Sudden blur of vision, diffuse corneal stroma deposits, EOM abnormalities, color vision disturbances, toxic amblyopia. |  | 
        |  | 
        
        | Term 
 
        | other NSAIDs, other than APAP & ASA |  | Definition 
 
        | Indomethacin (Indocin) Sulindac (clinoril) Ibuprofen (motrin) (Advil) Naproxen (Naprosyn, Anaprox) (Aleve) Diclofenac (Voltaren) |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | last resort NSAID drug 10-40X apirin potenscy, high tocicities Common Toxicitiy:  GIT & HA, same ocular toxicities. Rx only |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | has an active metabolite: more effective, 
less GI tox than indomethacin,Good for eldery px Rx Only |  | 
        |  | 
        
        | Term 
 
        | Ibuprofen (motrin, advil) |  | Definition 
 
        | More potent than aspirin, cause less GI toxicities, OVER THE COUNTER. |  | 
        |  | 
        
        | Term 
 
        | Naproxen (Naprosyn, Anaprox) *Aleve |  | Definition 
 
        | longer duration of action. subjectively better OTC |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | NSAID that decreases free arachidonic acid that results when this NSAID inhibits COX in tissues. Arachidonic acid is taken up into the cell membrane. Used for topical ocular pain due to laser treatments |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | Selective COX-2 inhibtor= used as antI-inflamm, analgesic and antipyretic. Little action on GI tract and platelet aggregation (COX-1 mediated effect). good for pt sensitive to GI effects of other NSAIDS |  | 
        |  | 
        
        | Term 
 
        | Celecoxib (celebrex) Toxicities? |  | Definition 
 
        | kidney problems, contraidicated in pt with aspirin sensitivity and sulfa allergies |  | 
        |  | 
        
        | Term 
 
        | Contraindications for ALL NSAIDs   |  | Definition 
 
        | Known Allergic Hypersensitivy, NSAID induced asthma or utricarial Asprin triad: asthma, nasal polyps, urticaria. Pregnancy: (need prostaglanding production for foramen ovale in infant heart to close before birth. Coronary Artery bypass grafting surgery- cos increased bleeding |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | physiologic role in glucose, aminoacid  & protein metabolism and use, Made by beta cels of pancreatic islets of langerlans: make pro-insulin Activate the uptake of glucose from blood plasma so we can use the energy from the glucose in our cells. |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | Insulin receptors at cell membrane, linked to tyrosine kinase, once  activated leads to phosphorylation of tyrosine and activation of GTP binding proteins. cascade to stimulate transcription factor to increase glucose metabolism proteins, increase of glucose uptake molecules, increase of molecules that take glucose and convert it to glycogen |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | Lack/ Apparent lack of insulin |  | 
        |  | 
        
        | Term 
 
        | Type 1- diabetes mellitus (IDDM) |  | Definition 
 
        | Absolute lack of insulin, insulin dependent DM:  no beta cell production, 
Treat w/ insulin to survive Onset: in childhood, unrelated to diet and exercise. |  | 
        |  | 
        
        | Term 
 
        | Type 2- diabetes mellitus |  | Definition 
 
        | 
Apparent lack of insulin OR decreased insulin senstivity,Have insulin but receptors are less sensitive to insulin, treat w/ oral agents (or insulin) Assoc: obesity and diet high in sugar, reduce or eliminate need for drugs with diet and exercise.   |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | 
Human insulin (recombinant DNA dervided, injection only)regular insulin (crystalline zinc or lispro) (humilin)Isophane insulin suspenstion (NPH) (Humulin N or Novolin N)Insulin glargine (lanthus)Combo can allow better control |  | 
        |  | 
        
        | Term 
 
        | regular insulin (crystalline zinc or lispro) (Humlin or humilog) |  | Definition 
 
        | 5-7hrs short acting like before meals; effects last throughout the day. |  | 
        |  | 
        
        | Term 
 
        | Isophane insulin suspension (NPH) (Humulin N or Novolin N) |  | Definition 
 
        | 18-24 hrs Intermediate acting |  | 
        |  | 
        
        | Term 
 
        | Insulin glargine (lanthus) |  | Definition 
 | 
        |  | 
        
        | Term 
 
        | oral agents to control blood glucose; Type 2 DM |  | Definition 
 
        | oral agents may be sufficient enough if insulin is available ie. functional beta cells exist. Problem: normally insulin stimulated by glucose and food ingestion so that glucose can be uptaked into tissues,  but with type 2 DM, decreased insulin sensitivity adn asynchronous release of insulin, not released appropriately so longer duration of high glucose levels. Goal: control glucose levels that damage vasculature leading to diabetic retinopathy, kidney damage & neuropathy |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | sulfonylureas & biguanides, glucosidase inhibtiors, glitazones* |  | 
        |  | 
        
        | Term 
 
        | Oral hypoglycemia Tx approach |  | Definition 
 
        | stimulates insulin release. |  | 
        |  | 
        
        | Term 
 
        | Antihyperglycemic (Antidiabetic) |  | Definition 
 
        | mimics other molecules that stimulate insulin release; decreases risk of hypoglycemia |  | 
        |  | 
        
        | Term 
 
        | MOA of Sulfonylureas (oral hypoglycemics) |  | Definition 
 
        | {More insulin released and more sensitive peripheral tissues} stimulate the release of insulin from functional beta, by binding to an ATP-dependent K+ channel leading to decrease in K+ efflux, increase in Ca2+ influx, which gives greater insulin release upon stimulation by glucose.   
increased sensitivity of peripheral tissues to the actions of insulin |  | 
        |  | 
        
        | Term 
 
        | Egs of Sulfonylureas which treat Type 2 DM, |  | Definition 
 
        | tolbumatide glipizide, glyburide, glimepiride. |  | 
        |  | 
        
        | Term 
 
        | Toxicities of Sulfonyurea oral hypoglycemics |  | Definition 
 
        | Hypoglycemia (profound) nausea rash blood disorders, jaundice, muscle weakness and ataxia, dizziness and mental confusion. |  | 
        |  | 
        
        | Term 
 
        | secratogues; oral hypoglycemics |  | Definition 
 
        | E.g Reaglinide (prandin) Nateglinide (stralix)   |  | 
        |  | 
        
        | Term 
 
        | MOA of secratogues; oral hypoglycemics |  | Definition 
 
        | 
Same receptor sites and mechanism as sulfonyl ureas: MOA: enter beta secretory cells, bind to ATP-dep K+ channel, decrease in K+ efflux & increase Ca2+ influx, increase in insulin secretion, 
increased sensitivity in peripheral tissues to insulin (includes glucose uptakes) |  | 
        |  | 
        
        | Term 
 
        | Tocicities of oral hypoglycemics: Secretagogues (Repaglinide and Nateglinide) |  | Definition 
 
        | Hypoglycemia (less likely than sulfas) Nausea &diarrhea Dyspesia NO cross allerigic hypersensitivity because these are not sulfa drugs. short duration therefore immediately before meal |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | do NOT stumulate insulin release form beta cells, much less likey to produce hypoglycemia. |  | 
        |  | 
        
        | Term 
 
        | MOA of metformin (glucophage), belongs to biguanides; antihyperglycemics |  | Definition 
 
        | 
decrease glucose output from liver (gluconeogenesis) which lowers glucose plasma levels.Increae insulin sensitivity on muscle & fat (due to lower glucose levels), glucose uptake into cells increased. |  | 
        |  | 
        
        | Term 
 
        | MOA of Biguanides (metformin); Antihyperglycemics |  | Definition 
 
        | reduce glucose output increase sensitivity on muscle and fat |  | 
        |  | 
        
        | Term 
 
        | Toxicities of Biguanides (metformin); Antihyperglycemics |  | Definition 
 
        | common: diarrhea, nausea, other GIT symptoms, Rare: significant increase in lactice acidosis especially renal insufficient pt. can kill!, megaloblastic anemia (rare) |  | 
        |  | 
        
        | Term 
 
        | MOA of Glucosidase inhibitors; Antihyperglycemics |  | Definition 
 
        | Inhibit GIT enzymes that break down complex carbs (complex carbs must be broken down or absorbed) eg. Acarbose(Procose) Miglitol (Glyset) |  | 
        |  | 
        
        | Term 
 
        | Toxicities of Glucosidase inhibitors |  | Definition 
 
        | cause GIT disturbacnes. diarrhea, pain, gas. Acarbose (Glucobay) (precose), Miglitol (Glyset) |  | 
        |  | 
        
        | Term 
 
        | what do  the antihyperlipidemics Thiazolidinediones (glitazones) do? |  | Definition 
 
        | anti hyperglycemic agents that increase sensitivity of insulin receptors.   |  | 
        |  | 
        
        | Term 
 
        | MOA of antihyperlipidemics Thiazolidinediones (glitazones) |  | Definition 
 
        | 
act as agonists to PPAR (peroxisome proliferator-activated receptor) to increase  gene transcription for "glucose uptake and utilization" proteins. Increase in glut-4 (transporter for glucose), lipoprotein lipase, fatty acid transporter protein etc |  | 
        |  | 
        
        | Term 
 
        | Toxicities of of antihyperlipidemics Thiazolidinediones (glitazones) |  | Definition 
 
        | Rosiglitazones (Avandia) Pioglitazones (Actos) 
weight gain & fluid retentionsignificat: hepatoxicity & congestive heart failure, |  | 
        |  | 
        
        | Term 
 
        | MOA of AntiHyperglycemic Agent Liraglutide (Victoza) Exenatide (byetta) |  | Definition 
 
        | Liraglutide (Victoza) Exenatide (Byetta) MOA: a GLP-1 receptor agonist  MOA: mimics physiologic hormone glucagon -like peptide (GLP-1) to: 
inhibit glucagon secretion,increase insulin secretion.delays gastric emptying.Close to normal physiologic response to a meal ingestion. |  | 
        |  | 
        
        | Term 
 
        | Toxicities of AntiHyperglycemic Agent Liraglutide (Victoza) |  | Definition 
 
        | Common: NVD More serious & less frequent: pancreatitis Possible thyroid carcinomaa |  | 
        |  | 
        
        | Term 
 
        | Toxicities of antihyperlipidemic: Exenatide (byetta) |  | Definition 
 
        | Common: NVD More serious,less frequent: pancreatitis anaphylactic reactions   |  | 
        |  | 
        
        | Term 
 
        | MOA of Antihyperglycemics Sitagliptin (Januvia) Saxagliptin (onglyza) Linagliptin (Tradjenta) which are DPP-4 inhibitors |  | Definition 
 
        | MOA: These dipeptidyl-peptidase 4 (DPP-4) inhibitors blocks the endogenous breakdown of  GLP-1. thus increasing the duration of incretin action to stimulate insulin release and inhibit glucagon release. (Incretin includes GLP-1 and others)  -orally effective!!! |  | 
        |  | 
        
        | Term 
 
        | Toxities of Antihyperglycemia Sitagliptin (Januvia) Saxagliptin (onglyza) Linagliptin (Tradjenta) |  | Definition 
 | 
        |  | 
        
        | Term 
 
        | which of the following DM 2 antihyperlipidemic drugs are orally effective? pick 3 a) Sitagliptin (januvia) b) Saxagliptin (Onglyza) c)Linagliptin (Tradjenta) d)Liraglutide, e) Exenatide |  | Definition 
 
        | Sitagliptin (januvia) Saxagliptin (Onglyza) Linagliptin (Tradjenta) |  | 
        |  | 
        
        | Term 
 
        | Toxicities of Antihyperglycemics: Sitagliptin (januvia) Saxagliptin (Onglyza) Linagliptin (Tradjenta) |  | Definition 
 
        | Common: upper respirator infxn (like a cold) Nasopharyngytis Headache More serious: pancreatitis, hypersenstitivity reactions |  | 
        |  | 
        
        | Term 
 
        | MOA of Inhibitors of type 2 sodium-glucose transporter (SGLT2) system.   |  | Definition 
 
        | MOA: inhibit SGLT2 in kidney. Normal= glucose in filtrate reabsorbed. Abnormal DM: too much glucose, not all rebasorbed so Polyuria. Inhibitors of SGLT2 system prevent reabsoprtion of glucoes from the kidney, thus allowing bllood glucose levels to be low. These are good for any pt. to lower blood glucose. |  | 
        |  |